JP2014530898A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530898A5
JP2014530898A5 JP2014537732A JP2014537732A JP2014530898A5 JP 2014530898 A5 JP2014530898 A5 JP 2014530898A5 JP 2014537732 A JP2014537732 A JP 2014537732A JP 2014537732 A JP2014537732 A JP 2014537732A JP 2014530898 A5 JP2014530898 A5 JP 2014530898A5
Authority
JP
Japan
Prior art keywords
antibody
agent
prostate cancer
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530898A (ja
JP6101274B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/052675 external-priority patent/WO2013061083A2/en
Publication of JP2014530898A publication Critical patent/JP2014530898A/ja
Publication of JP2014530898A5 publication Critical patent/JP2014530898A5/ja
Application granted granted Critical
Publication of JP6101274B2 publication Critical patent/JP6101274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537732A 2011-10-28 2012-10-26 治療剤およびその使用 Active JP6101274B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552796P 2011-10-28 2011-10-28
US61/552,796 2011-10-28
PCT/GB2012/052675 WO2013061083A2 (en) 2011-10-28 2012-10-26 Therapeutic agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2014530898A JP2014530898A (ja) 2014-11-20
JP2014530898A5 true JP2014530898A5 (cg-RX-API-DMAC10.html) 2015-12-10
JP6101274B2 JP6101274B2 (ja) 2017-03-22

Family

ID=47326213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537732A Active JP6101274B2 (ja) 2011-10-28 2012-10-26 治療剤およびその使用

Country Status (18)

Country Link
US (5) US9345782B2 (cg-RX-API-DMAC10.html)
EP (1) EP2771037B1 (cg-RX-API-DMAC10.html)
JP (1) JP6101274B2 (cg-RX-API-DMAC10.html)
KR (2) KR102232811B1 (cg-RX-API-DMAC10.html)
CN (1) CN104159618B (cg-RX-API-DMAC10.html)
AU (1) AU2012328173B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014010739A2 (cg-RX-API-DMAC10.html)
CA (1) CA2853669C (cg-RX-API-DMAC10.html)
DK (1) DK2771037T3 (cg-RX-API-DMAC10.html)
ES (1) ES2601459T3 (cg-RX-API-DMAC10.html)
IL (1) IL232262A (cg-RX-API-DMAC10.html)
LT (1) LT2771037T (cg-RX-API-DMAC10.html)
MX (1) MX353964B (cg-RX-API-DMAC10.html)
PL (1) PL2771037T3 (cg-RX-API-DMAC10.html)
PT (1) PT2771037T (cg-RX-API-DMAC10.html)
RU (1) RU2606773C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013061083A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201403372B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2771037T3 (en) 2011-10-28 2016-11-14 Fredax Ab Therapeutics and uses thereof
JP6308954B2 (ja) 2012-03-05 2018-04-11 オサケユキテュア・アークティック・パートナーズ・アクチボラゲットOy Arctic Partners Ab 前立腺癌のリスク及び前立腺容積を予測する方法及び装置
WO2015075445A1 (en) * 2013-11-19 2015-05-28 Fredax Ab Humanised anti kallikrein-2 antibody
GB2520353A (en) * 2013-11-19 2015-05-20 Fredax Ab Antibody polypeptides and uses thereof
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
WO2015189477A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
CA2982262A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
AU2016334715B2 (en) 2015-10-05 2023-02-02 Fredax Ab Humanized anti PSA (5A10) antibodies
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
US10183041B2 (en) 2017-04-12 2019-01-22 Vector Vitale Ip Llc Antibacterial composition and its use in treating bacterial infections
DE202017006951U1 (de) 2017-08-14 2019-02-07 Opko Diagnostics, Llc Multiplex-Assays zur Beurteilung des Prostatakrebsstatus
US12102694B2 (en) 2019-03-29 2024-10-01 National Institutes for Quantum Science and Technology Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus
TW202118792A (zh) * 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)
CR20220025A (es) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
CN112294760B (zh) * 2019-07-26 2025-12-12 宁波新致生物科技有限公司 一种液体制剂及其应用
CN112295112A (zh) * 2019-07-31 2021-02-02 广州康近医疗技术有限公司 前列腺癌β粒子腔内治疗机
PE20230389A1 (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
WO2025034663A2 (en) * 2023-08-04 2025-02-13 The General Hospital Corporation Differentiation of patients with and without prostate cancer using urine 1h nmr metabolomics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) * 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
WO1998021365A2 (en) 1996-11-14 1998-05-22 Mayo Foundation For Medical Education And Research Method for detection of metastatic prostate cancer
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
WO2001012218A1 (en) 1999-08-16 2001-02-22 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
CA2447695C (en) * 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
EP2347767A3 (en) * 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
US7492512B2 (en) 2004-07-23 2009-02-17 Mirage International Ltd. Wide field-of-view binocular device, system and kit
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
KR100723009B1 (ko) 2005-11-30 2007-05-29 한국원자력연구원 인간 p31 유전자를 함유하는 악성 종양 치료용 약학적조성물
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
SG177168A1 (en) * 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
DK2771037T3 (en) 2011-10-28 2016-11-14 Fredax Ab Therapeutics and uses thereof
WO2015075445A1 (en) 2013-11-19 2015-05-28 Fredax Ab Humanised anti kallikrein-2 antibody

Similar Documents

Publication Publication Date Title
RU2014121499A (ru) Терапевтические средства и их применение
Omarini et al. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments
Bilynsky et al. Radiation nanosensitizers in cancer therapy—From preclinical discoveries to the outcomes of early clinical trials
Vanan et al. DIPG in children–what can we learn from the past?
Velpurisiva et al. Nanoparticle design strategies for effective cancer immunotherapy
RU2016124229A (ru) Полипептиды антител и их применения
JP2010017189A5 (cg-RX-API-DMAC10.html)
Dietrich et al. Improving external beam radiotherapy by combination with internal irradiation
JP2016540503A5 (cg-RX-API-DMAC10.html)
Chester et al. Engineering antibodies for clinical applications in cancer
Kebudi et al. Management of diffuse pontine gliomas in children: recent developments
Kim et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy
JP2023165952A (ja) α線放射免疫療法薬とともにBCL-2インヒビターを使用してがんを処置するための方法
Engel et al. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins
Fionda et al. Abscopal effect and interventional oncology: state of art and future perspectives
Liu et al. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer
Allen et al. Quo vadis radiotherapy? Technological advances and the rising problems in cancer management
Liu et al. Autophagy inhibition improves the targeted radionuclide therapy efficacy of 131I-FAP-2286 in pancreatic cancer xenografts
CN111905101B (zh) 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法
CN113853220A (zh) 用于中枢神经系统肿瘤治疗的放射性微球
KR20230010656A (ko) 금 나노 입자 함유 의약
Bal et al. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy
KR20230038659A (ko) 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합
Chen et al. Imaging, biodistribution and efficacy evaluation of 188Re-human serum albumin microspheres via intraarterial route in an orthotopic hepatoma model
Khatua et al. Recent advances in the treatment of childhood brain tumors